1 |
Belisle JA, Gubbels JA, Raphael CA et al (2007) Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). Immunology 122, 418-429
DOI
|
2 |
Boivin M, Lane D, Piche A and Rancourt C (2009) CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecol Oncol 115, 407-413
DOI
|
3 |
Cherrin C, Haskell K, Howell B et al (2010) An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biol Ther 9, 493-503
DOI
|
4 |
Kazazi-Hyseni F, Beijnen JH and Schellens JH (2010) Bevacizumab. Oncologist 15, 819-825
DOI
|
5 |
Comamala M, Pinard M, Theriault C et al (2011) Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer 104, 989-999
DOI
|
6 |
Reinartz S, Failer S, Schuell T and Wagner U (2012) CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells. Eur J Cancer 48, 1558-1569
DOI
|
7 |
Yano S, Kondo K, Yamaguchi M et al (2003) Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 23, 3639-3650
|
8 |
Gipson IK, Spurr-Michaud S, Tisdale A and Menon BB (2014) Comparison of the transmembrane mucins MUC1 and MUC16 in epithelial barrier function. PLoS One 9, e100393
DOI
|
9 |
Aithal A, Rauth S, Kshirsagar P et al (2018) MUC16 as a novel target for cancer therapy. Expert Opin Ther Targets 22, 675-686
DOI
|
10 |
Kim N, Hong Y, Kwon D and Yoon S (2013) Somatic mutaome profile in human cancer tissues. Genomics Inform 11, 239-244
DOI
|
11 |
Das S, Rachagani S, Torres-Gonzalez MP et al (2015) Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells. Oncotarget 6, 5772-5787
DOI
|
12 |
Rump A, Morikawa Y, Tanaka M et al (2004) Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279, 9190-9198
DOI
|
13 |
Hattrup CL and Gendler SJ (2008) Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol 70, 431-457
DOI
|
14 |
Belisle JA, Horibata S, Jennifer GA et al (2010) Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer 9, 118
DOI
|
15 |
Felder M, Kapur A, Gonzalez-Bosquet J et al (2014) MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer 13, 129
DOI
|
16 |
Chen SH, Hung WC, Wang P, Paul C and Konstantopoulos K (2013) Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep 3, 1870
DOI
|
17 |
Giannakouros P, Matte I, Rancourt C and Piche A (2015) Transformation of NIH3T3 mouse fibroblast cells by MUC16 mucin (CA125) is driven by its cytoplasmic tail. Int J Oncol 46, 91-98
DOI
|
18 |
Schroeder JA, Thompson MC, Gardner MM and Gendler SJ (2001) Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogenactivated protein kinase activation in the mouse mammary gland. J Biol Chem 276, 13057-13064
DOI
|
19 |
Day FL, Jorissen RN, Lipton L et al (2013) PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin Cancer Res 19, 3285-3296
DOI
|
20 |
Betge J, Schneider NI, Harbaum L et al (2016) MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance. Virchows Arch 469, 255-265
DOI
|
21 |
Yin L, Wu Z, Avigan D et al (2011) MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells. Blood 117, 4863-4870
DOI
|
22 |
Yuan S, Liu Q, Hu Z et al (2018) Long non-coding RNA MUC5B-AS1 promotes metastasis through mutually regulating MUC5B expression in lung adenocarcinoma. Cell Death Dis 9, 450
DOI
|
23 |
Walsh MD, Clendenning M, Williamson E et al (2013) Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Mod Pathol 26, 1642-1656
DOI
|
24 |
Pigny P, Van Seuningen I, Desseyn JL et al (1996) Identification of a 42-kDa nuclear factor (NF1-MUC5B) from HT-29 MTX cells that binds to the 3' region of human mucin gene MUC5B. Biochem Biophys Res Commun 220, 186-191
DOI
|
25 |
Garcia EP, Tiscornia I, Libisch G et al (2016) MUC5B silencing reduces chemo-resistance of MCF-7 breast tumor cells and impairs maturation of dendritic cells. Int J Oncol 48, 2113-2123
DOI
|
26 |
Vincenzi B, Zoccoli A, Pantano F, Venditti O and Galluzzo S (2010) Cetuximab: from bench to bedside. Curr Cancer Drug Targets 10, 80-95
DOI
|
27 |
Huang L, Ren J, Chen D, Li Y, Kharbanda S and Kufe D (2003) MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol Ther 2, 702-706
|
28 |
Wen Y, Caffrey TC, Wheelock MJ, Johnson KR and Hollingsworth MA (2003) Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol Chem 278, 38029-38039
DOI
|
29 |
Theriault C, Pinard M, Comamala M et al (2011) MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol 121, 434-443
DOI
|
30 |
Snyder LC, Astsaturov I and Weiner LM (2005) Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer 5 Suppl 2, S71-80
DOI
|
31 |
Stacker SA and Achen MG (2013) The VEGF signaling pathway in cancer: the road ahead. Chin J Cancer 32, 297-302
DOI
|
32 |
Komatsu M, Arango ME and Carraway KL (2002) Synthesis and secretion of Muc4/sialomucin complex: implication of intracellular proteolysis. Biochem J 368, 41-48
DOI
|
33 |
Albrecht H and Carraway KL 3rd (2011) MUC1 and MUC4: switching the emphasis from large to small. Cancer Biother Radiopharm 26, 261-271
DOI
|
34 |
Yin L, Li Y, Ren J, Kuwahara H and Kufe D (2003) Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem 278, 35458-35464
DOI
|
35 |
Ling YH, Li T, Yuan Z, Haigentz M Jr, Weber TK and Perez-Soler R (2007) Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol Pharmacol 72, 248-258
DOI
|
36 |
Yap TA, Yan L, Patnaik A et al (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29, 4688-4695
DOI
|
37 |
Wood JP, Smith AJ, Bowman KJ, Thomas AL and Jones GD (2015) Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo. Cancer Med 4, 1309-1321
DOI
|
38 |
Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA and Gendler SJ (1998) Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 58, 315-321
|
39 |
Agata N, Ahmad R, Kawano T, Raina D, Kharbanda S and Kufe D (2008) MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8. Cancer Res 68, 6136-6144
DOI
|
40 |
Lahdaoui F, Messager M, Vincent A et al (2017) Depletion of MUC5B mucin in gastrointestinal cancer cells alters their tumorigenic properties: implication of the Wnt/beta-catenin pathway. Biochem J 474, 3733-3746
DOI
|
41 |
Lagow EL and Carson DD (2002) Synergistic stimulation of MUC1 expression in normal breast epithelia and breast cancer cells by interferon-gamma and tumor necrosis factor-alpha. J Cell Biochem 86, 759-772
DOI
|
42 |
Raina D, Kharbanda S and Kufe D (2004) The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem 279, 20607-20612
DOI
|
43 |
Yamada N, Nishida Y, Tsutsumida H et al (2008) MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells. Cancer Res 68, 2708-2716
DOI
|
44 |
Gendler SJ (2001) MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 6, 339-353
DOI
|
45 |
Levitin F, Stern O, Weiss M et al (2005) The MUC1 SEA module is a self-cleaving domain. J Biol Chem 280, 33374-33386
DOI
|
46 |
Wei X, Xu H and Kufe D (2005) Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 7, 167-178
DOI
|
47 |
Ahmad R, Raina D, Joshi MD et al (2009) MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. Cancer Res 69, 7013-7021
DOI
|
48 |
Jung YS, Wang W, Jun S et al (2018) Deregulation of CRAD-controlled cytoskeleton initiates mucinous colorectal cancer via beta-catenin. Nat Cell Biol 20, 1303-1314
DOI
|
49 |
Ookawa K, Kudo T, Aizawa S, Saito H and Tsuchida S (2002) Transcriptional activation of the MUC2 gene by p53. J Biol Chem 277, 48270-48275
DOI
|
50 |
Sipples R (2006) Common side effects of anti-EGFR therapy: acneform rash. Semin Oncol Nurs 22, 28-34
DOI
|
51 |
Sekine A, Akiyama Y, Yanagihara K and Yuasa Y (2006) Hath1 up-regulates gastric mucin gene expression in gastric cells. Biochem Biophys Res Commun 344, 1166-1171
DOI
|
52 |
Li Y, Bharti A, Chen D, Gong J and Kufe D (1998) Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol 18, 7216-7224
DOI
|
53 |
Ahmad R, Rajabi H, Kosugi M et al (2011) MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal 4, ra9
DOI
|
54 |
Wei X, Xu H and Kufe D (2006) MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell 21, 295-305
DOI
|
55 |
Pelaseyed T and Hansson GC (2020) Membrane mucins of the intestine at a glance. J Cell Sci 133
|
56 |
Shanmugam C, Jhala NC, Katkoori VR et al (2010) Prognostic value of mucin 4 expression in colorectal adenocarcinomas. Cancer 116, 3577-3586
DOI
|
57 |
Carraway KL 3rd, Rossi EA, Komatsu M et al (1999) An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling. J Biol Chem 274, 5263-5266
DOI
|
58 |
Gum JR Jr, Hicks JW, Gillespie AM et al (1999) Goblet cell-specific expression mediated by the MUC2 mucin gene promoter in the intestine of transgenic mice. Am J Physiol 276, G666-676
|
59 |
Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L and Hansson GC (2008) The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 105, 15064-15069
DOI
|
60 |
Peignon G, Durand A, Cacheux W et al (2011) Complex interplay between beta-catenin signalling and Notch effectors in intestinal tumorigenesis. Gut 60, 166-176
DOI
|
61 |
Haridas D, Ponnusamy MP, Chugh S, Lakshmanan I, Seshacharyulu P and Batra SK (2014) MUC16: molecular analysis and its functional implications in benign and malignant conditions. FASEB J 28, 4183-4199
DOI
|
62 |
Govindarajan B and Gipson IK (2010) Membrane-tethered mucins have multiple functions on the ocular surface. Exp Eye Res 90, 655-663
DOI
|
63 |
Tran DT and Ten Hagen KG (2013) Mucin-type O-glycosylation during development. J Biol Chem 288, 6921-6929
DOI
|
64 |
Kufe DW (2009) Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 9, 874-885
DOI
|
65 |
Wahrenbrock M, Borsig L, Le D, Varki N and Varki A (2003) Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 112, 853-862
DOI
|
66 |
Mekenkamp LJ, Heesterbeek KJ, Koopman M et al (2012) Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer 48, 501-509
DOI
|
67 |
Okudaira K, Kakar S, Cun L et al (2010) MUC2 gene promoter methylation in mucinous and non-mucinous colorectal cancer tissues. Int J Oncol 36, 765-775
|
68 |
Niv Y (2016) Mucin gene expression in the intestine of ulcerative colitis patients: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 28, 1241-1245
DOI
|
69 |
Garrido-Laguna I, Hong DS, Janku F et al (2012) KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One 7, e38033
DOI
|
70 |
Negri FV, Azzoni C, Bottarelli L et al (2013) Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. Anticancer Res 33, 4611-4617
|
71 |
Schroeder JA, Adriance MC, Thompson MC, Camenisch TD and Gendler SJ (2003) MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion. Oncogene 22, 1324-1332
DOI
|
72 |
Pochampalli MR, el Bejjani RM and Schroeder JA (2007) MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene 26, 1693-1701
DOI
|
73 |
Gubbels JA, Belisle J, Onda M et al (2006) Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 5, 50
DOI
|
74 |
Zhang L, Vlad A, Milcarek C and Finn OJ (2013) Human mucin MUC1 RNA undergoes different types of alternative splicing resulting in multiple isoforms. Cancer Immunol Immunother 62, 423-435
DOI
|
75 |
Zhang Y, Dong X, Bai L, Shang X and Zeng Y (2020) MUC1-induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway. Oncol Lett 20, 317
|
76 |
Ren J, Agata N, Chen D et al (2004) Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 5, 163-175
DOI
|
77 |
Dankort D, Filenova E, Collado M, Serrano M, Jones K and McMahon M (2007) A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21, 379-384
DOI
|
78 |
DuPage M, Dooley AL and Jacks T (2009) Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4, 1064-1072
DOI
|
79 |
Xu Y and Her C (2015) Inhibition of topoisomerase (DNA) I (TOP1): DNA damage repair and anticancer therapy. Biomolecules 5, 1652-1670
DOI
|
80 |
George J, Lim JS, Jang SJ et al (2015) Comprehensive genomic profiles of small cell lung cancer. Nature 524, 47-53
DOI
|
81 |
Hugen N, Brown G, Glynne-Jones R, de Wilt JH and Nagtegaal ID (2016) Advances in the care of patients with mucinous colorectal cancer. Nat Rev Clin Oncol 13, 361-369
DOI
|
82 |
Boland CR and Goel A (2010) Microsatellite instability in colorectal cancer. Gastroenterology 138, 2073-2087 e2073
DOI
|
83 |
Smagghe BJ, Stewart AK, Carter MG et al (2013) MUC1* ligand, NM23-H1, is a novel growth factor that maintains human stem cells in a more naive state. PLoS One 8, e58601
DOI
|
84 |
Robbe C, Capon C, Coddeville B and Michalski JC (2004) Structural diversity and specific distribution of O-glycans in normal human mucins along the intestinal tract. Biochem J 384, 307-316
DOI
|
85 |
Gunal A, Hui P, Kilic S et al (2013) KRAS mutations are associated with specific morphologic features in colon cancer. J Clin Gastroenterol 47, 509-514
DOI
|
86 |
Pai RK, Jayachandran P, Koong AC et al (2012) BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol 36, 744-752
DOI
|
87 |
Pereira MB, Dias AJ, Reis CA and Schmitt FC (2001) Immunohistochemical study of the expression of MUC5AC and MUC6 in breast carcinomas and adjacent breast tissues. J Clin Pathol 54, 210-213
DOI
|
88 |
Jung YS, Jun S, Kim MJ et al (2018) TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/beta-catenin signalling. Nat Cell Biol 20, 1421-1433
DOI
|
89 |
Losi L, Scarselli A, Benatti P et al (2004) Relationship between MUC5AC and altered expression of MLH1 protein in mucinous and non-mucinous colorectal carcinomas. Pathol Res Pract 200, 371-377
DOI
|
90 |
Rico SD, Hoflmayer D, Buscheck F et al (2020) Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer. Med Mol Morphol 54, 156-165
|
91 |
Dong Y, Zhou L, Zhao D et al (2020) MUC5AC enhances tumor heterogeneity in lung adenocarcinoma with mucin production and is associated with poor prognosis. Jpn J Clin Oncol 50, 701-711
DOI
|
92 |
Silva EM, Begnami MD, Fregnani JH et al (2008) Cadherin-catenin adhesion system and mucin expression: a comparison between young and older patients with gastric carcinoma. Gastric Cancer 11, 149-159
DOI
|
93 |
Pai P, Rachagani S, Dhawan P and Batra SK (2016) Mucins and Wnt/beta-catenin signaling in gastrointestinal cancers: an unholy nexus. Carcinogenesis 37, 223-232
DOI
|
94 |
Leir SH and Harris A (2011) MUC6 mucin expression inhibits tumor cell invasion. Exp Cell Res 317, 2408-2419
DOI
|
95 |
Nosho K, Kawasaki T, Ohnishi M et al (2008) PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 10, 534-541
DOI
|
96 |
Biemer-Huttmann AE, Walsh MD, McGuckin MA et al (2000) Mucin core protein expression in colorectal cancers with high levels of microsatellite instability indicates a novel pathway of morphogenesis. Clin Cancer Res 6, 1909-1916
|
97 |
Renaud F, Vincent A, Mariette C et al (2015) MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer. Int J Cancer 136, 2811-2821
DOI
|
98 |
Pothuraju R, Rachagani S, Krishn SR et al (2020) Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance. Mol Cancer 19, 37
DOI
|
99 |
Jun S, Jung YS, Suh HN et al (2016) LIG4 mediates Wnt signalling-induced radioresistance. Nat Commun 7, 10994
DOI
|
100 |
Mehla K and Singh PK (2014) MUC1: a novel metabolic master regulator. Biochim Biophys Acta 1845, 126-135
DOI
|
101 |
Nath S and Mukherjee P (2014) MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med 20, 332-342
DOI
|
102 |
Li Y, Ren J, Yu W et al (2001) The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J Biol Chem 276, 35239-35242
DOI
|
103 |
Desseyn JL, Aubert JP, Van Seuningen I, Porchet N and Laine A (1997) Genomic organization of the 3' region of the human mucin gene MUC5B. J Biol Chem 272, 16873-16883
DOI
|
104 |
Jung YS, Stratton SA, Lee SH et al (2021) TMEM9-v-ATPase activates Wnt/beta-catenin signaling via APC lysosomal degradation for liver regeneration and tumorigenesis. Hepatology 73, 776-794
DOI
|
105 |
Wang X, Jung YS, Jun S et al (2016) PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness. Nat Commun 7, 10633
DOI
|
106 |
Vincent A, Perrais M, Desseyn JL, Aubert JP, Pigny P and Van Seuningen I (2007) Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells. Oncogene 26, 6566-6576
DOI
|
107 |
Van Seuningen I, Perrais M, Pigny P, Porchet N and Aubert JP (2000) Sequence of the 5'-flanking region and promoter activity of the human mucin gene MUC5B in different phenotypes of colon cancer cells. Biochem J 348 Pt 3, 675-686
DOI
|
108 |
Van Seuningen I, Pigny P, Perrais M, Porchet N and Aubert JP (2001) Transcriptional regulation of the 11p15 mucin genes. Towards new biological tools in human therapy, in inflammatory diseases and cancer? Front Biosci 6, D1216-1234
|